Search research articles
Contact Us
Filters
Showing results (31-40 of 75) with videos related to
Page
of 8
Sort By:
Cell Reports
|
March 27, 2020
Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress
Junko Murai, Hongliang Zhang, Lorinc Pongor, et al.
The Journal of Cell Biology
|
May 5, 2004
Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia
Mitsuru Horiki, Takeshi Imamura, Mina Okamoto, et al.
Iscience
|
December 21, 2023
The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13
Kohei Fujiwara, Masashi Maekawa, Yuki Iimori, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms
|
September 11, 2014
SUMO-targeted ubiquitin ligase RNF4 plays a critical role in preventing chromosome loss
Kouji Hirota, Masataka Tsuda, Junko Murai, et al.
Molecular Cancer Therapeutics
|
May 22, 2023
Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Junko Murai, Michele Ceribelli, Haiqing Fu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 4, 2021
SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
Ukhyun Jo, Yasuhisa Murai, Sirisha Chakka, et al.
Cancer Research
|
November 3, 2012
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai, Shar-yin N Huang, Benu Brata Das, et al.
Molecular Cancer Therapeutics
|
December 21, 2013
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Laetitia Marzi, Ludmila Szabova, Melanie Gordon, et al.
Virchows Archiv : an International Journal of Pathology
|
June 1, 2020
Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq
Tsuyoshi Takashima, Naoya Sakamoto, Junko Murai, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 75) with videos related to
Sort By:
Page
of 8
Cell Reports
|
March 27, 2020
Chromatin Remodeling and Immediate Early Gene Activation by SLFN11 in Response to Replication Stress
Junko Murai, Hongliang Zhang, Lorinc Pongor, et al.
The Journal of Cell Biology
|
May 5, 2004
Smad6/Smurf1 overexpression in cartilage delays chondrocyte hypertrophy and causes dwarfism with osteopenia
Mitsuru Horiki, Takeshi Imamura, Mina Okamoto, et al.
Iscience
|
December 21, 2023
The crucial role of single-stranded DNA binding in enhancing sensitivity to DNA-damaging agents for Schlafen 11 and Schlafen 13
Kohei Fujiwara, Masashi Maekawa, Yuki Iimori, et al.
Genes to Cells : Devoted to Molecular & Cellular Mechanisms
|
September 11, 2014
SUMO-targeted ubiquitin ligase RNF4 plays a critical role in preventing chromosome loss
Kouji Hirota, Masataka Tsuda, Junko Murai, et al.
Molecular Cancer Therapeutics
|
May 22, 2023
Schlafen 11 (SLFN11) Kills Cancer Cells Undergoing Unscheduled Re-replication
Junko Murai, Michele Ceribelli, Haiqing Fu, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
February 4, 2021
SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
Ukhyun Jo, Yasuhisa Murai, Sirisha Chakka, et al.
Cancer Research
|
November 3, 2012
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai, Shar-yin N Huang, Benu Brata Das, et al.
Molecular Cancer Therapeutics
|
December 21, 2013
Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib
Junko Murai, Shar-Yin N Huang, Amèlie Renaud, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 15, 2019
The Indenoisoquinoline TOP1 Inhibitors Selectively Target Homologous Recombination-Deficient and Schlafen 11-Positive Cancer Cells and Synergize with Olaparib
Laetitia Marzi, Ludmila Szabova, Melanie Gordon, et al.
Virchows Archiv : an International Journal of Pathology
|
June 1, 2020
Immunohistochemical analysis of SLFN11 expression uncovers potential non-responders to DNA-damaging agents overlooked by tissue RNA-seq
Tsuyoshi Takashima, Naoya Sakamoto, Junko Murai, et al.
Page
of 8